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Abstract
Intravascular ultrasound (IVUS) is an invasive modality which provides cross-sectional images of a coronary artery. In
these images both the lumen and outer vessel wall can be identified and accurate estimations of their dimensions
and of the plaque burden can be obtained. In addition, further processing of the IVUS backscatter signal helps in
the characterization of the type of the plaque and thus it has been used to study the natural history of the
atherosclerotic evolution. On the other hand its indigenous limitations do not allow IVUS to assess accurately stent
struts coverage, existence of thrombus or exact site of plaque rupture and to identify some of the features
associated with increased plaque vulnerability. In order this information to be obtained, other modalities such as
optical coherence tomography, angioscopy, near infrared spectroscopy and intravascular magnetic resonance
imaging have either been utilized or are under evaluation. The aim of this review article is to present the current
utilities of IVUS in research and to discuss its advantages and disadvantages over the other imaging techniques.
Introduction
Utilization of conventional coronary angiography has
certain limitations in the prognosis of coronary athero-
sclerosis, as the risk of experiencing a coronary event
does not only depend upon the severity and extent of a
lesion, but also on the size, histology and biological
activity of the plaque. Some of these limitations can be
addressed by intravascular ultrasound (IVUS) a modality
which provides two dimensional (2-D) cross-sectional
arterial images. In these images the lumen, outer vessel
wall, plaque and stent can be identified and accurate
measurements can be obtained. The fact that it provides
reliable results in real time and it is widely available has
rendered it a useful tool in clinical practice and
research. Thus, though it is an expensive and time con-
suming procedure and caries a small risk of complica-
tions (mainly spasm but also the risk of embolism,
thrombus formation and dissection), IVUS is often used
to assess the severity of intermediate lesions, to guide
treatment in high risk patients and complex lesions and
to examine the final outcome after a percutaneous cor-
onary intervention (PCI) [1,2].
Apart from its clinical applications, IVUS has also
been proven a useful tool in research in the study of
plaque evolution and in the evaluation of new interven-
tional or pharmacological treatments. Recent develop-
ments in IVUS processing and especially the analysis of
intravascular ultrasound radiofrequency (IVUS-RF)
backscatter signal have provided further information
regarding the composition and mechanical properties of
t h ep l a q u ea n de n h a n c e dt h er o l eo fI V U Si nt h es t u d y
of atherosclerosis [3]. However, IVUS still has indigen-
ous limitations such as the noise and the low axial reso-
lution, which do not allow detailed visualisation of
certain lumen and plaque characteristics. For these lim-
itations to be addressed, alternative invasive modalities
with different strengths and weaknesses have been
developed such as angioscopy, optical coherence tomo-
graphy (OCT), near infrared spectroscopy (NIRS) and
intravascular magnetic resonance imaging (IV-MRI).
The aim of this review article is to discuss the advan-
tages and disadvantages of IVUS over the other imaging
techniques and highlight its value in research. * Correspondence: cbourantas@gmail.com
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The superiority of IVUS imaging over angiography were
obvious from its initial steps [4,5]. To facilitate its appli-
cation in research a number of tools were developed
that provided fast and reliable IVUS processing and
quantitative analysis [6-8]. This allowed the use of IVUS
in numerous studies which helped us to explain the
mechanisms of atherosclerotic process and affected the
evolution in interventional cardiology. In the early stages
of PCIs IVUS was used to elucidate the mechanisms of
action of balloon angioplasty (arterial expansion and pla-
que fracture) and understand the causes of restenosis
(vessel wall negative remodelling and intima prolifera-
tion) [9,10]. These data suggested the use of stents as it
was believed that they would reduce the risk of resteno-
sis. However, during the initial use of bare metal stents
(BMS) high rate of acute and sub-acute stent thrombosis
as well as restenosis were noted. IVUS imaging identi-
fied as predictors of sub-acute stent thrombosis the
incomplete stent strut apposition, the asymmetrical
stent expansion and the residual lumen narrowing and
also showed that restenosis mainly occurs within the
first 6 months post stent implantation [11]. To over-
come these problems post stent dilation with larger bal-
loons and higher pressures was recommended while
research was driven towards the creation of advanced
stent platforms and the development of drug eluting
stents (DES) [12].
II) Recent applications of IVUS imaging in
research
a) Study of plaque progression - vascular remodelling
Coronary angiography is unable to provide detailed
information regarding plaque burden, as initially athero-
sclerosis may not cause luminal narrowing accommodat-
ing the evolving plaque in the vessel wall which expands
outward (positive remodelling). On the other hand
IVUS permits complete vessel visualisation and accurate
assessment of the atherosclerotic burden and thus it
appears more sensitive than quantitative coronary angio-
graphy (QCA) in detecting the progression of athero-
sclerosis [13]. The fact that high plaque burden is
related to a higher risk of cardiovascular events has
a l l o w e dI V U Sm e a s u r e m e n t st ob eu s e da ss u r r o g a t e
endpoints, instead of clinical endpoints, in trials that
investigated the effect of several pharmacological treat-
ments on plaque progression [14,15]. In this way IVUS
imaging appeared a cost effective technique as it per-
mitted studies to be conducted with a smaller number
of patients and completed in shorter time interval.
Hence, today it is known that aggressive lipid-lowering
therapy (with high doses of atorvastatin or rosuvastatin)
induces plaque regression and that pioglitazone has a
favourable effect on coronary atherosclerosis [16-20].
Similarly, the CAMELOT study used IVUS to show that
amlodipine reduces plaque burden while the PERSPEC-
TIVE study demonstrated that perindopril does not
affect the progression of the atheroma [21,22]. In addi-
tion, serial IVUS examinations were implemented to
study the effect of new drugs such as the reconstituted
HDL (CSL-111), the dalapladip (a lipoprotein-associated
phospholipase A2 inhibitor) and the pactimibe (a non-
selective inhibitor of acyl-coenzyme A:cholesterol acyl-
transferase) on plaque development. In these studies it
was found that all the new treatments had a neutral
effect on plaque burden though dalapladip appeared to
reduce the lipid core expansion [23-25].
The ability of IVUS to display both the plaque and the
whole vessel wall provided us with an insight into the
mechanisms, and the prognostic value of vascular remo-
delling. IVUS has been used to show that negative
remodelling (defined as a shrinkage of the vessel wall at
the lesion site) is more common in elderly patients and
stable plaques, whilst on the other hand it appears that
plaques with positive remodelling (defined as vessel wall
expansion at the lesion site) contain more lipid-rich
components, and are associated with an increased risk
for acute coronary events [26,27].
Compared to other invasive imaging techniques IVUS
is superior in quantifying changes in plaque volume and
measuring vessel wall dimensions and thus is the prefer-
able modality for assessing the effect of pharmacological
treatment on coronary atherosclerosis. Angioscopy can-
not be used to measure the plaque as it provides only
imaging of the luminal surface and gives no data on the
vessel wall. On the other hand, OCT although allows
imaging of the atheroma, and more accurate computa-
tion of plaque volume in case of calcium deposits, since
it lacks the shadowing artefacts, often cannot portray the
whole vessel as it has poor tissue penetration (Figure 1).
To address this drawback several new approaches have
been proposed (e.g. spectral radar OCT, use of a parallel
ultrasound beam, image processing techniques etc.) how-
ever, further development is necessary before these tech-
niques can be used in vivo for the evaluation of vascular
pathology [28].
b) Characterisation of the type of the plaque - vulnerable
plaque detection
It is well known that IVUS has limited capability in asses-
sing plaque composition and detecting the features asso-
ciated with plaque’s vulnerability. To address these
drawbacks analysis of IVUS radiofrequency backscatter
signal has been proposed. This signal processing approach
was validated using histopathologic findings as gold stan-
dard and it was found that it can identify the type of the
plaque with high sensitivity, specificity and predictive
accuracy [29,30]. This ability, the comprehensive images
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allowed the broad use of IVUS-RF in the study of plaque
development. Several IVUS-RF based studies have showed
that the composition of the atheroma is affected by co-
morbidities such as hypertension (increased fibrous pla-
ques), diabetes mellitus (larger lipid cores and less fibrous
p l a q u e s )o rt h ep r e s e n c eo ft h em e t a b o l i cs y n d r o m e
(increased lipid rich plaques); while others demonstrated
that therapy with statins has favourable effects, as it stabi-
lizes the plaque by reducing its lipid component [31-33].
Kubo et al. used serial IVUS-RF imaging to investigate
the natural evolution of non-obstructive plaques and
showed that in contrast to fibrous and calficied plaques
which remain unchanged the intimal thickening and
thick cap fibroatheromas may evolve to thin cap
fibroatheromas at 12 months follow-up [34]. Moreover,
the PROSPECT trial used IVUS-RF to study the natural
progress of atherosclerosis in 700 patients who presented
with acute coronary syndrome. All patients underwent
successful PCI and three vessel imaging with IVUS and
IVUS-RF. At 3 years follow-up major adverse cardiac
events occurred in 20.4% of the patients. After examining
the imaging data at follow-up it was found that presence
of a thin-cap fibroatheroma, plaque burden ≥70% and a
minimum luminal area ≤4m m
2 were associated with an
increased risk for cardiovascular events.
However, although IVUS-RF appears reliable in char-
acterising the type of the plaque and studying its
evolution, it has limited capability in identifying several
features which according to Naghavi et al. are associated
with increased vulnerability (Table 1) [35]. Autopsy stu-
dies showed that a vulnerable plaque is mainly found in
segments with positive remodelling, is infiltrated by
macrophages and consists of a lipid rich core covered
by a thin fibrous cap which is maybe disrupted. The fact
that IVUS-RF has a reduced axial resolution (range:
100-200 μm )r e s t r i c t si t sa b i l i t yt oi d e n t i f ys o m eo f
these features (e.g. plaque disruption, infiltration of
macrophages) and to measure the thickness of the
fibrous cap [36]. To enhance the effectiveness of IVUS
in detecting features associated with increased vulner-
ability several methodologies have been proposed such
as palpography that measures the local strain of the pla-
que and contrast enhanced IVUS which in a single
study was implemented to detect the vasa vasorm and
increased neovascularization [37-39]. Though the first
results appear promising, natural history and multicen-
tre randomized interventional trials should be per-
formed in order to establish their ability to identify high
risk plaques.
OCT has emerged as a promising imaging modality
for evaluating plaque composition and assessing plaque’s
vulnerability. The high resolution of OCT imaging
allows the identification of lipid pools and in contrast to
IVUS, detection of the internal and external elastic
lamina [40,41]. Another advantage of OCT is the lack of
shadowing artefacts, in case of calcium deposits that
enables visualisation of the adjacent tissues. OCT also
provides accurate quantification of fibrous cap thickness,
allows reliable evaluation of cap disruption and erosion
and is able to clearly visualise the presence and type of
thrombus [36,42]. Finally, it has been speculated that
OCT enables detection of macrophages infiltration,
though this has not been evaluated in large scale trials
[43]. A limitation of this modality is the restricted axial
penetration that may impede the estimation of lipid
pool dimensions, and identification of positive remodel-
ling. To overcome this, combination of IVUS-RF and
OCT imaging has been suggested [44].
Angioscopy, though not useful in characterising pla-
que’s constitution, has been used for the identification
of the high risk plaques as it can reliably demonstrate
the presence and the type of thrombus and has similar
sensitivity with IVUS in detecting plaque erosion and
disruption [36]. In addition, it has been showed that the
colour of the plaque depends on the thickness of the
fibrous cap, with the yellow plaques having the histolo-
gical characteristics of a vulnerable plaque (a thin
fibrous cap covering a lipid-rich core) and white plaques
being stable having thick fibrous caps [45]. However,
routine use of angioscopy is severely limited as it
requires full obliteration of the vessel and disruption of
Figure 1 OCT imaging may allow visualisation of the vessel
wall behind a calcified plaque (A) but on the other hand often
fails to fully visualise the arterial wall because of its poor
penetration (B). The limitation of IVUS to identify the type and the
extent of the plaque behind the calcium (arrow) (C) has been
successfully addressed by IVUS-RF analysis (D).
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visualize long coronary segments.
c) Evaluation of drug eluting and bioabsorbable stents
IVUS is a useful tool in evaluating the efficacy of different
invasive treatments, identifying predictors of in-stent
restenosis and stent thrombosis and understanding the
underlying mechanisms. Its ability to measure neointimal
hyperplasia has allowed IVUS to be used in landmark
studies which examined the effectiveness of DES over
BMS [46,47]. It has also been implemented to assess the
performance of new platforms (e.g. MAHOROBA study
showed failure of the tacrolimus-eluting stent to prevent
neointimal hyperplasia) and to compare the efficacy of
treatment options for in-stent restenosis [48-50]. More-
over, IVUS provided an insight into some of the mechan-
isms associated with stent thrombosis in DES era and
thus today it is known that stent underexpansion, resi-
dual reference segment stenosis, incomplete stent apposi-
tion and coronary dissection after DES implantation are
associated with an increased risk for stent thrombosis
and future major adverse cardiac events [51-53].
IVUS has also been implemented to test the safety pro-
file, vessel wall reactions, and mechanical behavior of
bioabsorbable stents. These stents, been constructed by a
material which is gradually absorbed, are expected to not
impair the image quality of the non-invasive imaging mod-
alities and to have less late thrombosis rates. Several studies
used IVUS to assess luminal dimensions and remodeling
after bioabsorbable stent implantation [54-56]. The
ABSORB found favorable results while the PROGRESS-
AMS showed a significant late luminal loss after the
implantation of a bioabsorbable magnesium stent fact that
was attributed to recoil and neointimal hyperplasia [55,56].
In the ABSORB study a multitude of imaging modalities
(QCA, IVUS, IVUS-RF, palpography, OCT, and computed
tomographic (CT) coronary angiography) were implemen-
ted to study the behavior of the bioabsorbable everolimus-
eluting stent. In this study IVUS and IVUS-RF appeared
useful in measuring the luminal and plaque dimensions
after stent implantation and assessing alterations in plaque
constitution whereas palpography was used to evaluate
changes in the deformability of the vessel wall caused by
the stent absorption [57,58].
OCT appears equally useful in assessing the efficacy of
stents. An advantage of OCT is that it can accurately
detect thrombus and vessel trauma (e.g. depth of dissec-
tions caused by balloon inflations and cuts in the athero-
sclerotic plaque made by the blades of cutting balloons)
during invasive treatments and detect the presence (or
absence) of stent struts coverage [59]. Furthermore, OCT
is superior to IVUS in identifying incomplete stent appo-
sition and stent malapposition but in contrast to IVUS it
cannot assess the effect of vascular remodelling to late
stent malapposition (Figure 2) [60,61].
Angioscopy has also been utilised, but in less extent,
to assess the efficacy of invasive treatments. Comparing
to IVUS, angioscopy allows more reliable evaluation of
vascular trauma after PCIs and can be used to provide
an insight into stent struts coverage after DES implanta-
tion [62]. On the other hand it fails to quantify stent
struts coverage and luminal dimensions and cannot
assess stent apposition and vascular remodelling.
d) The role of heamodynamics on the atherosclerotic process
Over the last decade IVUS has been combined with
angiography for the reconstruction of coronary arteries
[63,64]. The obtained models which currently constitute
Table 1 Histological features of vulnerable plaque - ability of invasive imaging modalities in identifying vulnerable
plaque characteristics
Criteria for defining a vulnerable plaque Intravascular imaging modalities
Major Criteria IVUS, IVUS-RF OCT Angioscopy NIRS* IV-MRI*
Active inflammation - + - - -
Thin fibrous cap ++ +++ ++ - +
Lipid core +++ +++ - ++ ++
Disrupted plaques + +++ ++ - -
Stenosis > 90% +++ + - - ++
Minor Criteria
Superficial calcified nodule - ++ - - -
Yellow colour on angioscopy plaque - - +++ - -
Intraplaque haemorrhage - + - - -
Endothelial dysfunction - - - - -
Positive remodelling +++ + - - ++
IVUS, intravascular ultrasound; RF, radiofrequency analysis; OCT, optical coherence tomography; NIRS, near infrared spectroscopy; IV-MRI, intravascular magnetic
resonance imaging. Methods’ ability to identify vulnerable plaque characteristics is graded as: unable (-), low capability (+), moderate capability (++) and high
capability (+++). The evaluation of the methods that have not been used in clinical practice (indicated with *) was based on the in vitro and ex vivo studies.
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fully and comprehensive arterial representation and have
been used to investigate the role of local heamody-
namics in the atherosclerotic process (Figure 3). Several
investigators implemented these models to demonstrate
that low and oscillatory shear stresses are associated
with an increased risk for in-stent restenosis and athero-
sclerosis progression in native coronary segments and
coronary bifurcations while recently, it was shown that
low shear stresses not only act as an atherogenic factor
but also promote the development of vulnerable plaque
[65-68]. These studies have provided useful information
and helped us to explain the regional localisation of
atherosclerosis and understand the role of flow
dynamics in plaque evolution and destabilisation [69].
e) Future developments
NIRS relies on the principle that different organic mole-
cules absorb and scatter NIRS light to different degrees
Figure 2 IVUS images showing optimal stent expansion (A);
neointima formation (B) and late stent malaposition 6 months
after a DES implantation (C). OCT imaging allows not only
assessment of stent expansion but also evaluation of stent struts
coverage (absence of coverage (D) vs. complete coverage (E)) and
measurement of neointimal hyperplasia (F).
Figure 3 3-D reconstruction of a coronary artery and blood flow simulation. (A) Extraction of the IVUS path from biplane angiography;
(B) semi-automated border detection of the IVUS images; (C) placement of the detected borders onto the catheter path and determination of
their absolute orientation; (D) virtual endoscopy of the reconstructed vessel; (E) blood flow simulation into the final model and determination of
the endothelial shear stresses.
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detect lipid core containing coronary plaques has been
known for over a decade. However, only recently tech-
nology enabled the development of a catheter suitable
for the human coronary artery. The device is attached
to a console, which interprets the NIRS signals, and pro-
duces three outputs: the chemogram, the block chemo-
gram and the lipid core burden index none of which
require additional processing (Figure 4). A significant
limitation of this modality is its inability to provide
information regarding the dimensions and the morphol-
o g yo ft h er e g i o n so fi n t e r e s t .T h i sl i m i t a t i o nh a sb e e n
addressed by a new catheter that combines both a NIRS
and a 40 MHz IVUS probe and enables co-localization
of lipid core with structure. The feasibility of this hybrid
modality has already been examined in-vivo and the
first results appear promising for the future [70].
IV-MRI appears also to be a potentially useful techni-
que for tissue characterisation [71]. Nevertheless,
limitations, such as the increased size of the catheters
and the risk of vessel wall heating, caused by the intense
radiofrequency administration required for complete tis-
sue characterisation and anatomic depiction, need to be
addressed before this method can be used in clinical
practice [72].
Finally, new non-invasive imaging modalities are likely
to emerge in the near future as an attractive alternative
in the study of atherosclerosis. The combination of posi-
tron emission tomography with CT imaging has already
allowed the anatomic identification of nuclear tracers
attracted by inflamed plaques, and thus this approach
can be used for the detection of vulnerable plaques [73].
CT coronary angiography is another promising techni-
que. Currently, it allows visualization of plaque and dif-
ferentiation of calcified from non calcified atheroma.
However, it cannot discriminate fibrous from lipid pla-
ques and has limited capability in assessing plaque bur-
den in de-novo and especially in stented segments
Figure 4 The outputs from the Near-infrared spectroscopy device. (A) The chemogram is a map of the measured probability of the
presence of lipid core plaque from each scanned arterial segment and displays pullback position against circumferential position of the
measurement in degrees. The device attributes a yellow colour to those regions with the highest probability of lipid core plaque, whilst red
represents those with the lowest. In this example, a high probability of lipid core is detected at 30-40 cm proximal to the origin of the pullback.
(B) A block chemogram provides a summary of the raw data from the chemogram and displays the probability that a lipid core is present for all
measurements in a 2 mm block of coronary artery. The order of probability for the presence of lipid core plaque from highest to lowest is
yellow, light brown, brown, and red. (C and D) The lipid core burden index, a numerical value, which ranges from 0-1000, gives an impression of
the lipid content within the artery. The chemogram (C) has very little in the way of yellow regions, compared to the chemogram (D), reflecting
this, the respective lipid core burden indexes are 4 and 143.
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which limits coronary visualization; hence further devel-
opment is required before its implementation in the
clinical and research arena.
Conclusions
Through our review it is apparent that today there is a
multitude of imaging modalities able to assess different
morphological and functional features of the coronary
arteries. Amongst these IVUS constitutes a valuable tool
in research as it is the gold standard for studying plaque
development and assessing the effectiveness of pharmaco-
logical treatments on plaque’s evolution (Table 2). Though
it is the most widespread invasive imaging modality it has
significant intrinsic limitations being the considerable
noise and the low axial resolution which does not allow
detailed assessment of luminal morphology and meticu-
lous visualisation of plaque characteristics. Thus, alterna-
tive intravascular imaging techniques have been
introduced which provide additional information regard-
ing the composition and vulnerability of the plaque and
allow more accurate evaluation of stent deployment and
struts’ coverage. The combination of IVUS with these
modalities, either as independent or as hybrid imaging,
m a ya l l o wi nt h ef u t u r eam o r ed e t a i l e di n s i g h ti n t ot h e
mechanisms of plaque progression-regression and provide
better evaluation of the different therapeutic strategies.
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